Perioperative intravenous iron; an upfront therapy for treating anaemia and reducing transfusion requirements;Hierro intravenoso perioperatorio; una opción terapéutica para el tratamiento de la anemia y la reducción de los requerimientos de transfusión

Nutricion Hospitalaria

Volumn 27, Issue 6, 2012, Pages 1817-1836

  Muñoz, Manuel ^a   Gomez Ramirez S ^b   Martin Montanez E ^a   Pavia J ^a   Cuenca, J ^c   Garcia Erce J A ^d  

^a UNIVERSITY OF MÁLAGA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^c HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^d HOSPITAL SAN JORGE   (Spain)

Author keywords

Allogenic transfusion; Efficacy; Intravenous iron; Perioperative anaemia; Safety

Indexed keywords

IRON DERIVATIVE;

ANEMIA, IRON-DEFICIENCY; BLOOD AUTOTRANSFUSION; BLOOD TRANSFUSION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PERIOPERATIVE PERIOD; PROCEDURES; STATISTICS AND NUMERICAL DATA;

ANEMIA, IRON-DEFICIENCY; BLOOD TRANSFUSION; BLOOD TRANSFUSION, AUTOLOGOUS; HUMANS; INJECTIONS, INTRAVENOUS; IRON COMPOUNDS; PERIOPERATIVE CARE;

EID: 84874693505     PISSN: 02121611     EISSN: 16995198     Source Type: Journal    
DOI: 10.3305/nh.2012.27.6.6087     Document Type: Review

References (169)

1. Shander A, Knight K, Thurer R, Adamson J, Spence R. Prevalence and outcomes of anemia in surgery: a systematic review of the literature. Am J Med 2004; 116: 58S-69S.
2. Muñoz M, García-Erce JA, Remacha AF. Disorders of iron metabolism. Part II: Iron deficiency and iron overload. J Clin Pathol 2011; 64: 287-296 (doi:10.1136/jcp.2010.086991).
3. Muñoz M, García-Erce JA, Remacha AF. Disorders of iron metabolism. Part I: Molecular basis of iron homeostasis. J Clin Pathol 2011: 64: 281-286 (doi:10.1136/jcp.2010.079046).
4. García-Erce JA, Cuenca J, Solano VM. Predictive factors for transfusion requirements in patients over 65 years old with subcapital hip fracture. Med Clin (Barc) 2003; 120: 161-6.
5. García-Erce JA, Manuel Solano V, Cuenca J, Ortega P. Preoperative hemoglobin as the only predictive factor of transfusional needs in knee arthroplasty. Rev Esp Anestesiol Reanim 2002; 49: 254-60.
6. Marik PE, Corwin HL. Efficacy of red blood cell transfusion in the critically ill: a systematic review of the literature. Crit Care Med 2008; 36: 2667-74.
7. Wu WC, Smith TS, Henderson WG, Eaton CB, Poses RM, Uttley G et al. Operative blood loss, blood transfusion, and 30-day mortality in older patients after major noncardiac surgery. Ann Surg 2010; 252: 11-17.
8. Glance LG, Dick AW, Mukamel DB, Fleming FJ, Zollo RA, Wissler R et al. Association between intraoperative blood transfusion and mortality and morbidity in patients undergoing noncardiac surgery. Anesthesiology 2011; 114: 283-92.
9. Pedersen AB, Mehner F, Overgaard S, Johnsen SP. Allogeneic blood transfusion and prognosis following total hip replacement: a population-based follow up study. BMC Musculoskeletal Disorders 2009; 10: 167 doi:10.1186/1471-2474-10-167.
10. Mortensen FV, Jensen LS, Sørensen HT, Pedersen L. Causespecific mortality associated with leukoreduced, buffy coatdepleted, or no blood transfusion after elective surgery for colorectal cancer: a posttrial 15-year follow-up study. Transfusion 2011; 51: 259-63.
11. Koch M, Antolovic D, Reissfelder C, Rahbari NN, Holoch J, Michalski I et al. Leucocyte-depleted blood transfusion is an independent predictor of surgical morbidity in patients undergoing elective colon cancer surgery-a single-center analysis of 531 patients. Ann Surg Oncol 2011; 18: 1404-11.
12. Amato A, Pescatori M. Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst Rev 2006; (1): CD005033.
13. Kulier A, Levin J, Moser R, Rumpold-Seitlinger G, Tudor IC, Snyder-Ramos SA, Moehnle P, Mangano DT. Impact of preoperative anemia on outcome in patients undergoing coronary artery bypass graft surgery. Circulation 2007; 116: 471-9.
14. Karkouti K, Wijeysundera DN, Beattie WS. Risk associated with preoperative anemia in cardiac surgery: a multicenter cohort study. Circulation 2008; 117: 478-84.
15. Khanna MP, Hebert PC, Fergusson DA. Review of the clinical practice literature on patient characteristics associated with perioperative allogeneic red blood cell transfusion. Transfus Med Rev 2003; 17: 110-119.
16. Koch CG, Weng Y, Zhou SX, Savino JS, Mathew JP, Hsu PH et al. Prevalence of risk factors, and not gender per se, determines short-and long-term survival alter coronary artery bypass surgery. J Cardiothorac Vasc Anesth 2003; 17: 585-593.
17. Wu WC, Schifftner TL, Henderson WG, Eaton CB, Poses RM, Uttley G et al. Preoperative hematocrit levels and postoperative outcomes in older patients undergoing noncardiac surgery. JAMA 2007; 297: 2481-8.
18. Musallam KM, Tamim HM, Richards T, Spahn DR, Rosendaal FR, Habbal A et al. Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study. Lancet 2011; 378: 1396-407.
19. Leichtle SW, Mouawad NJ, Lampman R, Singal B, Cleary RK. Does Preoperative Anemia Adversely Affect Colon and Rectal Surgery Outcomes? J Am Coll Surg 2011; 212: 187-94.
20. Beris P, Muñoz M, García-Erce JA, Thomas D, Maniatis A, Van der Linden P. Perioperative anaemia management: consensus statement on the role of intravenous iron. Br J Anaesth 2008; 100: 599-604.
21. Jahn MR, Andreasen HB, Fütterer S, Nawroth T, Schünemann V, Kolb U et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer®), a new intravenous iron preparation and its clinical implications. Eur J Pharm Biopharm 2011; 78: 480-91.
22. Muñoz M, Martín-Montañez E. Ferric carboxymaltose for the treatment of iron-deficiency anemia. Expert Opin Pharmacother 2012; 13: 907-21.
23. Cançado RD, Muñoz M. Intravenous iron therapy: how far have we come? Rev Bras Hematol Hemoter 2011; 33: 461-9.
24. Breymann C. The use of iron sucrose complex for anemia in pregnancy and the postpartum period. Semin Haematol 2006; 43 (Suppl. 6): S28-S31.
25. Breymann C, Richter C, Hüttner C, Huch R, Huch A. Effectivenes of recombinant erythropoietin and iron sucrose vs. iron therapy only, in patients with postpartum anaemia and blunted erythropoiesis. Eur J Clin Invest 2000; 30: 154-6.
26. Broche DE, Gay C, Armand-Branger S, Grangeasse L, Terzibachian JJ. Anémies sévères du post-parum inmediat. Practique clinique et intérêt du fer par voie intraveineuse. Gynecol Obstet Fertil 2004; 32: 613-9.
27. Wågström E, Åkesson A, Van Rooijen M, Larson B, Bremme K. Erythropoietin and intravenous iron therapy in postpartum anaemia. Acta Obstet Gynecol 2007; 86: 957-62.
28. Dede A, Uygur D, Yilmaz B, Mungan T, Ugur M. Intravenous iron sucrose complex vs. oral ferrous sulfate for postpartun iron deficiency anemia. Int J Gynecol Obstet 2005; 90: 238-9.
29. Bhandal N, Russell R. Intravenous versus oral iron therapy for postpartum anaemia. Br J Obstet Gynaecol 2006; 113: 1248-52.
30. Gredilla E, Gimeno M, Canser E, Martínez B, Pérez-Ferrer A, Gilsanz F. Tratamiento de la anemia en el postparto y en el postoperatorio inmediato de cirugía ginecológica, con hierro intravenoso. Rev Esp Anestesiol Reanim 2006; 53: 208-13.
31. Armand-Ugón R, Cheong T, Matapa G, Rojo-Sanchís A, Bisbe E, Muñoz M. Efficay of intravenous iron for treating postpartum anemia in low-resource African countries. A pilot study in Malawi. J Womens Health (Larchmt) 2011; 20: 123-7.
32. Van Wyck DB, Martens MG, Seid MH, Baker JB, Mangione A. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomised controlled trial. Obstet Gynecol 2007; 110: 267-78.
33. Seid MH, Derman RJ, Baker JB, Banach W, Goldberg C, Rogers R. Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial. Am J Obstet Gynecol 2008; 199: 435-7.
34. Breymann C, Gliga F, Bejenariu C, Strizhova N. Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia. Int J Gynaecol Obstet 2008; 101: 67-73.
35. Larson B, Bremme K, Clyne N, Nordstrom L. Preoperative treatment of anemic women with epoetin beta. Acta Obstet Gynecol Scand 2001; 80: 559-62.
36. Dousias V, Paraskevaidis E, Dalkalitsis N, Tsanadis G, Navrozoglou I, Lolis D. Recombinant human erythropoietin in mildly anemic women before total hysterectomy. Clin Exp Obstet Gynecol 2003; 30: 235-8.
37. Díez-Lobo AI, Fisac-Martín MP, Bermejo-Aycar I, Muñoz M. Preoperative intravenous iron administration corrects anaemia and reduces transfusion requirement in women undergoing abdominal hysterectomy. Transfus Alter Transfus Med 2007; 9: 114-9.
38. Van Wyck DB, Mangione A, Morrison J, Hadley PE, Jehle JA, Goodnough LT. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion 2009; 49: 2719-28.
39. DeCherney AH, Bachmann G, Isaacson K, Gall S. Postoperative fatigue negatively impacts the daily lives of patients recovering from hysterectomy. Obstet Gynecol 2002; 99: 51-7.
40. De la Morena F, Gisbert JP. Anemia in inflammatory bowel disease. Rev Esp Enf Dig 2008; 100: 285-293.
41. M'Koma AE. Follow-up results of hematology data before and after restorative proctocolectomy: clinical outcome. Dis Colon Rectum 1994; 37: 932-7.
42. Gisbert JP, Gomollón F. Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease. Am J Gastroenterol 2008; 103: 1299-1307.
43. Gasche C, Kulnigg S. Intravenous iron in inflammatory bowel disease. Semin Hematol 2006; 43 (Suppl. 6): S18-S22.
44. Erichsen K, Ulvik RJ, Nysaeter G, Johansen J, Ostborg J, Berstad A et al. Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease. Scand J Gastroenterol 2005; 40: 1058-65.
45. Gasche C, Berstad A, Befrits R, Beglinger C, Dignass A, Erichsen K et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis 2007; 13: 1545-53.
46. Gasche C, Waldhoer T, Feichtenschlager T, Male C, Mayer A, Mittermaier C et al. Prediction of response to iron sucrose in inflammatory bowel disease-associated anemia. Am J Gastroenterol 2001; 96: 2382-7.
47. Bodemar G, Kechagias S, Almer S, Danielson BG. Treatment of anemia in inflammatory bowel disease with iron sucrose. Scand J Gastroenterol 2004; 39: 454-8.
48. Schroder O, Mickisck O, Seidler U, de Weerth A, Dignass AU, Herfath H et al. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease-A randomized, controlled, open-label, multicenter study. Am J Gastroenterol 2005; 100: 2503-9.
49. García-López S, Gomollón F, García-Erce JA, Araméndiz R, Sicilia B, Vicente R. Intravenous iron sucrose: a simple, safe, and quick method to treat anemia secondary to digestive diseases (AGA Abstract 576). Gastroenterology 2006; 130 (Suppl. 2): A-84.
50. Kulnigg S, Stoinov S, Simanenkov V, Dudar LV, Karnafel W, Garcia LC et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol 2008; 103: 1182-92.
51. Lindgren S, Wikman O, Befrits R, Blom H, Eriksson A, Granno C et al. Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: A randomized, controlled, evaluator-blind, multicentre study. Scand J Gastroenterol 2009; 27: 1-8.
52. Gisbert JP, Bermejo F, Pajares R, Pérez-Calle JL, Rodríguez M, Algaba A et al. Oral and intravenous iron treatment in inflammatory bowel disease: Hematological response and quality of life improvement. Inflamm Bowel Dis 2009; 15: 1485-91.
53. Evstatiev R, Marteau P, Iqbal T, Khalif IL, Stein J, Bokemeyer B et al. FERGIcor, randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease disease. Gastroenterology 2011; 141: 846-53.
54. Kulnigg S, Teischinger L, Dejaco C, Waldhör T, Gasche C. Rapid recurrence of IBD-associated anemia and iron deficiency after intravenous iron sucrose and erythropoietin treatment. Am J Gastroenterol 2009; 104: 1460-7.
55. Mamula P, Piccoli DA, Peck SN, Markowitz JE, Baldassano RN. Total dose intravenous infusion of iron dextran for irondeficiency anemia in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2002; 34: 286-90.
56. Shokoohi A, Stanworth S, Mistry D, Lamb S, Staves J, Murphy MF. The risks of Red Cell Transfusion for hip fracture surgery in the elderly. Vox Sang 2012 (DOI: 10.1111/j.1423-0410. 2012.01606.x)
57. Zauber NP, Zauber AG, Gordon FJ, Tillis AC, Leeds HC, Berman E et al. Iron supplementation after femoral head replacement for patients with normal iron stores. JAMA 1992; 267: 525-7.
58. Prasad N, Rajamani V, Hullin D, Murray JM. Post-operative anaemia in femoral neck fracture patients: does it need treatment? A single blinded prospective randomised controlled trial. Injury 2009; 40: 1073-6.
59. Parker MJ. Iron supplementation for anemia after hip fracture surgery: a randomized trial of 300 patients. J Bone Joint Surg Am 2010; 92-A: 265-9.
60. Cuenca J, Garcia-Erce JA, Munoz M, Izuel M, Martinez AA, Herrera A. Patients with pertrochanteric hip fracture may benefit from preoperative intravenous iron therapy: a pilot study. Transfusion 2004; 44: 1447-52.
61. Cuenca J, Garcia-Erce JA, Martinez AA, Solano VM, Molina J, Munoz M. Role of parenteral iron in the management of anaemia in the elderly patient undergoing displaced subcapital hip fracture repair: preliminary data. Arch Orthop Trauma Surg 2005; 125: 342-7.
62. Serrano-Trenas JA, Font-Ugalde P, Muñoz-Cabello L, Castro-Chofles L, Rodríguez-Fernández PJ, Carpintero-Benítez P. Role of perioperative intravenous iron therapy in elderly hip fracture patients. A single center randomized controlled trial. Transfusion 2011; 51: 97-104.
63. García-Erce JA, Cuenca J, Muñoz M, Izuel M, Martínez AA, Herrera A et al. Perioperative stimulation of erythropoiesis with intravenous iron and erythropoietin reduces transfusion requirements in patients with hip fracture. A prospective observational study. Vox Sanguinis 2005; 89: 235-43.
64. García-Erce JA, Cuenca J, Haman-Alcober S, Martínez AA, Herrera A, Muñoz M. Efficacy of preoperative recombinant human erythropoietin administration for reducing transfusion requirements in patients undergoing surgery for hip fracture repair. An observational cohort study. Vox Sang 2009; 97:260-7.
65. Spahn DR. Anemia and patient blood management in hip and knee surgery. A systematic review of the literature. Anesthesiology 2010; 113: 482-95.
66. Saleh E, McClelland DBL, Hay A, Semple D, Walsh TS. Prevalence of anaemia before major joint arthroplasty and the potential impact of pre-operative investigation and correction on peri-operative blood transfusions. Br J Anaesth 2007; 99: 801-8.
67. Bisbe E, Castillo J, Sáez M, Santiveri X, Ruiz A, Muñoz M. Prevalence of preoperative anemia and hematinic deficiencies in patients scheduled for major orthopedic surgery. Transfus Altern Transfus Med 2008; 4: 166-73.
68. Cuenca J, Garcia-Erce JA, Martinez F, Cardona R, Perez-Serrano L, Munoz M. Preoperative haematinics and transfusion protocol reduce the need for transfusion after total knee replacement. Int J Surg 2007; 5: 89-94.
69. Andrews CM, Lane DW, Bradley JG. Iron pre-load for major joint replacement. Transfus Med 1997; 7: 281-6.
70. Lachance K, Savoie M, Bernard M, Rochon S, Fafard J, Robitaille R et al. Oral ferrous sulfate does not increase preoperative hemoglobin in patients scheduled for hip or knee arthroplasty. Ann Pharmacother 2011; 45: 764-70.
71. Beris P, Muñoz M, García-Erce JA, Thomas D, Maniatis A, Van der Linden P. Perioperative anaemia management: consensus statement on the role of intravenous iron. Br J Anaesth 2008; 100: 599-604.
72. Bisbe E, García-Erce JA, Díez-Lobo AI, Muñoz M; Anaemia Working Group España. A multicentre comparative study on the efficacy of intravenous ferric carboxymaltose and iron sucrose for correcting preoperative anaemia in patients undergoing major elective surgery. Br J Anaesth 2011; 107: 477-8 (Research letter).
73. Theusinger OM, Leyvraz PF, Schanz U, Seifert B, Spahn DR. Treatment of iron deficiency anemia in orthopedic surgery with intravenous iron: efficacy and limits: a prospective study. Anesthesiology 2007; 107: 923-7.
74. González-Porras JR, Colado E, Conde MP, Lopez T, Nieto MJ, Corral M. An individualized pre-operative blood saving protocol can increase pre-operative haemoglobin levels and reduce the need for transfusion in elective total hip or knee arthroplasty. Transfus Med 2009; 19: 35-42.
75. Goodnough LT, Maniatis A, Earnshaw P, BenoniG, Beris P, Bisbe E et al. Detection, evaluation, and management of preoperative anaemia in the elective orthopaedic surgical patient-NATA guidelines. Br J Anaesth 2011; 1: 13-22.
76. Cuenca J, Garcia-Erce JA, Martinez F, Perez-Serrano L, Herrera A, Muñoz M. Perioperative intravenous iron, with or without erythropoietin, plus restrictive transfusion protocol reduce the need for allogenic blood after knee replacement surgery. Transfusion 2006; 46: 1112-9.
77. Weber EWG, Slappendel R, Hémon Y, Mähler S, Dálen T, Rouwet E et al. Effects of epoetin alfa on blood transfusions and postoperative recovery in orthopaedic surgery: the European Epoetin Alfa Surgery Trial (EEST). Eur J Anaesthesiol 2005; 22; 249-257.
78. García-Erce JA, Cuenca J, Martínez F, Cardona R, Pérez-Serrano L, Muñoz M. Perioperative intravenous iron preserves iron stores and may hasten the recovery from postoperative anaemia after knee replacement surgery. Transf Med 2006; 16: 335-41.
79. Weber EW, Slappendel R, Hémon Y, Mähler S, Dalén T, Rouwet E et al. Effects of epoetin alfa on blood transfusions and postoperative recovery in orthopaedic surgery: the European Epoetin Alfa Surgery Trial (EEST). Eur J Anaesthesiol 2005; 22: 249-57.
80. Na HS, Shin SY, Hwang JY, Jeon YT, Kim CS, Do SH. Effects of intravenous iron combined with low-dose recombinant human erythropoietin on transfusion requirements in iron-deficient patients undergoing bilateral total knee replacement arthroplasty. Transfusion 2011; 51: 118-24.
81. Weatherall M, Maling TJ. Oral iron therapy for anaemia after orthopaedic surgery: randomized clinical trial. ANZ J Surg 2004; 74: 1049-51.
82. Sutton PM, Cresswell T, Livesey JP, Speed K, Bagga T. Treatment of anaemia after joint replacement. J Bone Joint Surg Br 2004; 86: 31-3.
83. Mundy GM, Birtwistle SJ, Power RA. The effect of iron supplementation on the level of haemoglobin after lower limb arthroplasty. J Bone Joint Surg Br 2005; 87-B: 213-17.
84. Bernière J, Dehullu JP, Gall O, Murat I. Intravenous iron in the treatment of postoperative anemia in surgery of the spine in infants and adolescents. Rev Chir Orthop 1998; 84: 319-22.
85. Karkouti K, McCluskey SA, Ghannam M, Salpeter MJ, Quirt I, Yau TM. Intravenous iron and recombinant erythropoietin for the treatment of postoperative anemia. Can J Anesth 2006; 53: 11-9.
86. Muñoz M, Naveira E, Seara J, Cordero J. Effects of postoperative intravenous iron on transfusion requirements after lower limb arthroplasty. Br J Anaesth 2012; 108: 532-4.
87. Muñoz M, Ariza D, Gómez-Ramírez S, Hernández P, García-Erce JA, Leal-Noval SR. Preoperative anemia in elective cardiac surgery: prevalence, risk factors, and influence on postoperative outcome. Transfus Altern Transfus Med 2010; 11: 47-56.
88. Muñoz M, Ariza D, Leal Noval SR, García Erce JA. Cardiac surgery in the elderly: prevalence and consequences of preoperative anemia. Med Clin (Barc) 2008; 131: 276-7.
89. Piednoir P, Allou N, Driss F, Longrois D, Philip I, Beaumont C et al. Preoperative iron deficiency increases transfusion requirements and fatigue in cardiac surgery patients: a prospective observational study. Eur J Anaesthesiol 2011; 28: 796-801.
90. Muñoz M, García-Erce JA, Leal-Noval SR. Perioperative transfusion in anaemic patients undergoing coronary bypass. Lancet 2002; 360: 1427-1428.
91. Muñoz M, Leal-Noval R, García-Erce JA. Intravenous iron in cardiac surgery. Semin Hematol 2006; 43 (Suppl. 6): S39-S42.
92. Alghamdi AA, Albanna MJ, Guru V, Brister SJ. Does the use of erythropoietin reduce the risk of exposure to allogeneic blood transfusion in cardiac surgery? A systematic review and meta-analysis. J Card Surg 2006; 21: 320-6.
93. Cladellas M, Farré N, Comín-Colet J, Gómez M, Meroño O, Bosch MA et al. Effects of preoperative intravenous erythropoietin plus iron on outcome in anemic patients after cardiac valve replacement. Am J Cardiol 2012 Jul 6. [Epub ahead of print].
94. Weltert L, D'Alessandro S, Nardella S, Girola F, Bellisario A, Maselli D, De Paulis R. Preoperative very short-term, highdose erythropoietin administration diminishes blood transfusion rate in off-pump coronary artery bypass: a randomized blind controlled study. J Thorac Cardiovasc Surg 2010; 139: 621-6.
95. Yoo YC, Shim JK, Kim JC, Jo YY, Lee JH, Kwak YL. Effect of single recombinant human erythropoietin injection on transfusion requirements in preoperatively anemic patients undergoing valvular heart surgery. Anesthesiology 2011; 115: 929-37.
96. Crosby L, Palarski VA, Cottington E, Cmolik B. Iron supplementation for acute blood loss anemia after coronary artery bypass surgery: a randomized, placebo-controlled study. Heart Lung 1994; 23: 493-9.
97. Madi-Jebara S, Sleilaty GS, Achouh PE, Yazigi AG, Haddad FA, Hayek GM, et al. Postoperative intravenous iron used alone or in combination with low-dose erythropoietin in not effective for correction of anemia after cardiac surgery. J Cardiothorac Vasc Anesth 2004; 18: 59-63.
98. Hulin S, Durandy Y. Intérêt du fer intraveineux dans les anémies induites par l'hémodilution en chirurgie cardiaque pédiatrique. Ann Fran Anesth Reanim 2005; 24: 1262-1265, 2005.
99. Torres S, Kuo YH, Morris K, Neibart R, Holtz JB, Davis JM. Intravenous iron following cardiac surgery does not increase the infection rate. Surg Infect (Larchmt) 2006; 7: 361-366.
100. Cappell MS, Goldberg ES. The relationship between the clinical presentation and spread of colon cancer in 315 consecutive patients: a significant trend of earlier cancer detection from 1982 through 1988 at a university hospital. J Clin Gastroenterol 1992; 14: 227-35.
101. Sadahiro S, Suzuki T, Tokunaga N, Mukai M, Tajima T, Makuuchi H et al. Anemia in patients with colorectal cancer. J Gastroenterol 1998; 33:488-49.
102. Edna TH, Karlsen V, Jullumstrø E, Lydersen S. Prevalence of anaemia at diagnosis of colorectal cancer: assessment of associated risk factors. Hepatogastroenterology 2012; 59: 713-6.
103. Kim J, Konyalian V, Huynh R, Mittal R, Stamos M, Kumar R. Identification of predictive factors for perioperative blood transfusion in colorectal resection patients. Int J Colorectal Dis 2007; 22: 1493-7.
104. Beale AL, Penney MD, Allison MC. The prevalence of iron deficiency among patients presenting with colorectal cancer. Colorectal Dis 2005; 7: 398-402.
105. Prutki M, Poljak-Blazi M, Jakopovic M, Tomas D, Stipancic I, Zarkovic N. Altered iron metabolism, transferrin receptor 1 and ferritin in patients with colon cancer. Cancer Lett 2006; 238: 188-96.
106. Okuyama M, Ikeda K, Shibata T, Tsukahara Y, Kitada M, Shimano T. Preoperative iron supplementation and intraoperative transfusion during colorectal cancer surgery. Surg Today 2005; 35: 36-40.
107. Lidder PG, Sanders G, Whitehead E, Douie WJ, Mellor N, Lewis SJ et al. Pre-operative oral iron supplementation reduces blood transfusion in colorectal surgery-a prospective, randomised, controlled trial. Ann R Coll Surg Engl 2007; 89: 418-21.
108. Quinn M, Drummond RJ, Ross F, Murray J, Murphy J, Macdonald A. Short course pre-operative ferrous sulphate supplementation-is it worthwhile in patients with colorectal cancer? Ann R Coll Surg Engl 2010; 92: 569-72.
109. Edwards TJ, Noble EJ, Durran A, Mellor N, Hosie KB. Randomized clinical trial of preoperative intravenous iron sucrose to reduce blood transfusion in anaemic patients after colorectal cancer surgery. Br J Surg 2009; 96: 1122-8.
110. Ranganathan P, Pramesh CS. Letter 1: Randomized clinical trial of preoperative intravenous iron sucrose to reduce blood transfusion in anaemic patients after colorectal cancer surgery (Br J Surg 2009; 96: 1122-1128). Br J Surg 2010; 97: 297-8.
111. Simpson JA, Tselepis C, Iqbal T, Acheson AG, Brookes MJ. Letter 2: Randomized clinical trial of preoperative intravenous iron sucrose to reduce blood transfusion in anaemic patients after colorectal cancer surgery (Br J Surg 2009; 96: 1122-1128). Br J Surg 2010; 97: 298-9.
112. Campos A, Sevilla I, Baca JJ, Romero A, Ramírez G, Muñoz M. Perioperative iron therapy and transfusion requirements in patients undergoing surgery for colon cancer. Preliminary results [abstract]. Transfus Altern Transfus Med 2005; 8 (1 Suppl.): 96.
113. Díaz Espallardo C, Laso Morales MJ, Colilles Calvet C, Mora López L, Roig Martínez I, Martínez Marín MT. [The multidisciplinary approach is useful for optimising preoperative haemoglobin in colorectal cancer surgery]. Cir Esp 2011; 89: 392-9.
114. Harju E. Empty iron stores as a significant risk factor in abdominal surgery. J Parent Enteral Nutr 1988; 12: 282-285.
115. Zago L, Dupraz H, Torino F, Río ME. Estado nutricional preoperatorio y riesgo quirúrgico. Identificación de marcadores bioquímicos promisorios. Nutr Hosp 2010; 25: 91-98.
116. Titos-Arcos JC, Soria-Aledo V, Carrillo-Alcaraz A, Ventura-López M, Palacios-Muñoz S, Pellicer-Franco E. Is intravenous iron useful for reducing transfusions in surgically treated colorectal cancer patients? World J Surg 2012; 36: 1893-7.
117. Muñoz M, Campos A, García-Erce JA. Intravenous iron in colorectal cancer surgery. Semin Hematol 2006; 43 (Suppl. 6): S36-S38.
118. Devon KM, McLeod RS. Pre and peri-operative erythropoietin for reducing allogeneic blood transfusions in colorectal cancer surgery. Cochrane Database Syst Rev 2009: CD007148.
119. Vanrenterghem Y, Ponticelli C, Morales JM, Abramowicz D, Baboolal K, Eklund B et al. Prevalence and management of anemia in renal transplant recipients: a European survey. Am J Transplant 2003; 3: 835-845.
120. Turkowski-Duhem A, Kamar N, Cointault O, Lavayssiere L, Esposito L, Fillola G, et al. Predictive factors of postrenal transplant anemia. Transplantation Proc 2005; 37: 1009-1011.
121. Yorgin PD, Belson A, Sanchez J, Al Uzri AY, Sarwal M, Bloch DA et al. Unexpectedly high prevalence of posttransplant anemia in pedriatric and young adult renal transplant recipients. Am J Kidney Dis 2002; 40: 1306-1318.
122. Van Biesen W, Vanholder R, Veys N, Verbeke F, Lameire N. Efficacy of erythropoietin administration in the treatment of anemia immediately after renal transplantation. Transplantation 2005; 79: 367-368.
123. Jimeno L, Rodado R, Campos M, Lanuza M. Iron deficiency-An underrecognized problem in nonamemic and erythrocytic kidney transplant recipients: risk and effects of ACEI and iron treatment. Transplantation Proc 2005; 37: 1007-1008.
124. Mudge DW, Tan KS, Miles R, Johnson DW, Badve SV, Campbell SB et al. A randomized controlled trial of intravenous or oral iron for posttransplant anemia in kidney transplantation. Transplantation 2012; 93: 822-6.
125. Gillespie RS, Symons JM. Sodium ferric gluconate for posttransplant anemia in pediatric and young adult renal transplant recipients. Pediatr Transplantation 2005; 9: 43-46.
126. Ezekowitz JA, McAlister FA, Amstromg PW. Anemia is common in heart failure and is associated with poor outcomes. Insights from a cohort of 12,065 patients with new-onset heart failure. Circulation 2003; 107: 223-225.
127. Silverberg DS, Wexler D, Blum M, Keren G, Sheps D, Leibovitch E et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 2000; 35: 1737-44.
128. Silverberg DS, Wexler D, Sheps D, Blum M, Keren G, Baruch R et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 2001; 37: 1775-80.
129. Mancini DM, Katz SD, Lang CC, LaManca J, Hudaihed A, Androne AS. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 2003; 107: 294-299.
130. Palazzuoli A, Silverberg D, Iovine F, Capobianco S, Giannotti G, Calabro A, Campagna MS, Nuti, R: Erythropoietin improves anemia exercise tolerance and renal function and reduces Btype natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J 2006; 152: 1096. e9-21096. e15.
131. Comín-Colet J, Ruiz S, Cladellas M, Rizzo M, Torres A, Bruguera J. A pilot evaluation of the long-term effect of combined therapy with intravenous iron sucrose and erythropoietin in elderly patients with advanced chronic heart failure and cardio-renal anemia syndrome: influence on neurohormonal activation and clinical outcomes. J Card Fail 2009; 15: 727-35.
132. Bolger AP, Bartlett FR, Penston HS, O'Leary J, Pollock N, Kaprielian R, et al. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol 2006; 48: 1225-7.
133. Toblli JE, Lombraña A, Duarte P, Di Gennaro F. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol 2007; 50: 1657-65.
134. Okonko DO, Grzeslo A, Witkowski T, Mandal AK, Slater RM, Roughton M, et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol 2008; 51: 103-12.
135. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361: 2436-48.
136. Arutyunov G, Bylova N, Ivleva A, Kobalava Z. The safety of intravenous (IV) ferric carboxymaltose versus IV iron sucrose on patients with chronic heart failure (CHF) and chronic kidney disease (CKD) with iron deficincy (ID). Eur J Heart Fail 2009; 8 (Suppl. 2009): ii71.
137. Silverberg DS, Blum M, Agbaria Z, Deutsch V, Irony M, Schwartz D et al. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period. Clin Nephrol 2001; 55: 212-219.
138. Sargent JA, Acchiardo SR. Iron requirements in hemodialysis. Blood Purif 2004; 22: 112-123.
139. Mircescu G, Garneata L, Capusa C, Ursea N. Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients. Nephrol Dial Transplant 2006; 21: 120-4.
140. Covic A, Mircescu G. The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multi-centre, open-label, clinical study. Nephrol Dial Transplant 2010; 25: 2722-30.
141. Qunibi WJ, Martínez C, Smith M, Benjamin J. Mangione A, Roger SD. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron fro treatment of iron deficiency anemia of non-dialysis-dependent chronic kidney disease. Nephrol Dial Transplant 2011; 26: 1599-607.
142. Schaefer RM, Khasabov NN, Todorov NG, Evenepoel P. Intravenous ferric carboxymaltose or iron sucrose to treat iron deficiency anaemia in haemodialysis patients. Poster presented at the XLV ERA-EDTA Congress, May 10-1 2008.
143. García-Erce JA, Fernández C, Lao J, Muñoz M. Meta-análisis de la eficacia y seguridad de hierro endovenoso en el tratamiento de la anemia, en pacientes oncológicos tratados con agentes estimulantes de la eritropoyesis. Hematologica (edición española) 2009; 94 (extra 2): 138.
144. Hedenus M, Birgegård G, Näsman P, Ahlberg L, Karlsson T, Lauri B et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia 2007; 21: 627-32.
145. Kim YT, Kim SW, Yoon BS, Cho HJ, Nahm EJ, Kim SH et al. Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy. Gynecol Oncol 2007; 105: 199-204.
146. Dangsuwan P, Manchana T. Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. Gynecol Oncol 2010; 116: 522-5.
147. Muñoz M, Mazure RA, Culebras JM. Obesidad y sistema inmune. Nutr Hosp 2004; 19: 319-24.
148. Muñoz M, Botella-Romero F, Gómez-Ramírez S, Campos A, García-Erce JA. Iron deficiency and anaemia in bariatric surgical patients: causes, diagnosis and proper management. Nutr Hosp 2009; 24: 759-73.
149. Muñoz M, Leal-Noval SR, García-Erce JA, Naveira E. Prevalencia y manejo de la anemia en el paciente crítico. Med Intensiva 2007; 31: 388-398.
150. Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Abraham E et al. The CRIT study: anemia and blood transfusion in the critically ill. Current clinical practice in the United States. Crit Care Med 2004; 32: 39-52.
151. Vincent JL, Baron JF, Reinhart K, Gattinoni L, Thijs L, Webb A et al. Anemia and blood transfusion in critically ill patients. JAMA 2002; 288: 1499-507.
152. Muñoz M, Romero A, Morales M, Campos A, García-Erce JA, Ramírez G. Iron metabolism, inflammation, and anemia in critically ill patients. A cross-sectional study. Nutr Hosp 2005; 20: 110-6.
153. Pieracci FM, Henderson P, Macmillan Rodney JR, Holena DN, Genisca A, Benkert IIS, et al. Randomized, double-blind, placebo-controlled trial of effects of enteral iron supplementation on anemia and risk of infection during surgical critical illness. Surg Infect 2009; 10: 9-19.
154. Van Iperen CE, Gaillard CA, Kraaijenhagen RJ, Braam BG, Marx JJ, van de Wiel A. Response of erythropoiesis and iron metabolism to recombinant human erythropoietin in intensive care unit patients. Crit Care Med 2000; 28: 2773-8.
155. Muñoz M, García-Erce JA, Leal-Noval SR. ¿La eritropoyetina humana recombinante es aún una alternativa válida para el tratamiento de la anemia del paciente crítico? Med Clin (Barc) 2009; 132: 749-55.
156. Chertow GM, Mason PD, Vaaga-Nilsen O, Ahlmén J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006; 21: 378-82.
157. Stainsby D, Jones H, Asher D, Atterbury C, Boncinelli A, Brant L et al. SHOT Steering Group. Serious hazards of transfusion: a decade of hemovigilance in the UK. Transfus Med Rev 2006; 20: 273-82.
158. Bailie GR. Comparison of rates of reported adverse events associated with i.v. iron products in the United States. Am J Health Syst Pharm 2012; 69: 310-20.
159. Aronoff GR. Safety of intravenous iron in clinical practice: implications for anemia management protocols. J Am Soc Nephrol 2004; 15: S99-S106.
160. Coyne DW, Auerbach M. Anemia management in chronic kidney disease: Intravenous iron steps forward. Am J Hematology 2010; 85: 311-2.
161. Silverstein SB, Rodgers GM. Parenteral iron therapy options. Am J Hematol 2004; 76: 74-78.
162. Rodgers GM, Auerbach M, Cella D, Chertow GM, Coyne DW, Glaspy JA et al. High-molecular weight iron dextran: a wolf in sheep's clothing? J Am Soc Nephrol 2008; 19: 833-4.
163. Fishbane S, Kowalski EA. The comparative safety of intravenous iron dextran, iron saccharate, and sodium ferric gluconate. Semin Dial 2000; 13: 381-4.
164. Van Wyck DB. Labile iron. manifestations and clinical implications. J Am Soc Nephrol 2004; 15 (Suppl. 2): S107-S111.
165. Weiss G. Iron and immunity: a double-edged sword. Eur J Clin Invest 2002; 32 (Suppl. 1): 70-78.
166. García-Erce JA, Cuenca J, Gómez-Ramírez S, Villar I, Herrera A, Muñoz M. Posibilidades de tratamiento de la anemia perioperatoria en cirugía ortopédica y traumatología. Anemia 2009; 2: 17-27.
167. Izuel Rami M, García Erce JA, Gómez-Barrera M, Cuenca Espiérrez J, Abad Sazatornil R, Rabanaque Hernández MJ. Relación de la transfusión y la ferropenia con la infección nosocomial en pacientes con fractura de cadera. Med Clin (Barc) 2008; 131: 647-52.
168. McDougall I. Experience with intravenous iron in nephrology. Semin Hematol 2006; 43 (Suppl. 6): S9-S12.
169. Cortés-Berdonces M, García Martín A, León Sanz M. Anemia del paciente crítico y quirúrgico; tratamiento con hierro intravenoso. Nutr Hosp 2011; 27: 7-12.